About Coverage Alpha

The gap

Every quarter, the same thing happens. A pharmaceutical company reports earnings. Sell-side analysts translate the print for investors — revenue, EPS, guidance, the stock reaction. Trade press summarizes the highlights. And the single most consequential thing said on the call, the part about net price, formulary positioning, or payer mix, gets a sentence and a shrug.

Meanwhile the people whose job depends on that sentence — market access teams, pricing strategists, business development groups — are left assembling the picture themselves. They read the transcript, cross reference the formulary changes they happen to know about, and reason from experience. Every quarter, in parallel, at a dozen companies at once.

The tools that exist do not close the gap. Equity research is written for investors and treats access as a footnote. Formulary databases track coverage accurately but backward, with no narrative and no connection to what management just said. Consultants can connect the dots, and do it well — quarterly, at fifty thousand dollars, for one client at a time.

Nobody publishes the seam. That is what Coverage Alpha is.

What alpha means here

In finance, alpha is the excess return attributable to skill rather than to the market's general movement. Beta is what you get for showing up. Alpha is what you get for knowing something others don't.

Everyone reading a pharmaceutical earnings call has access to the same transcript. That is beta — the commodity layer, freely available, priced in within minutes. It is page one of every issue, and it is deliberately thorough.

The alpha is page two: what the quarter means for formulary positioning, rebate mechanics, contracting leverage, and deal appetite. That is the part that cannot be extracted from the transcript by anyone who has not sat in the rooms where those decisions get made.

The method

Page one — what they said

• Extraction. The quarter in management's own words, including the pricing and access exchanges from Q&A, with a key metrics table showing variance against consensus and prior year.
• Delta. What moved versus the prior quarter, and a judgment on which moves are strategy rather than noise.
• Point of view. What it means, stated plainly, with peer comparison against the closest competitor on the metric that matters for access.

Page two — what it means

• Market access. Formulary and contracting read-through, gross-to-net and rebate implications, launch access signals, and utilization management dynamics.
• Business development. Pipeline and asset-level read-through, buyer-appetite signals, and the diligence assumptions that just went stale.
• What we're watching. A dated list of the formulary and policy events that will confirm or kill each thesis, which doubles as the publication calendar between earnings seasons.

Cadence

An issue publishes within 48 hours of each earnings call across the coverage universe: Eli Lilly, Novo Nordisk, Novartis, Bristol Myers Squibb, UCB, Pfizer, Sanofi and Regeneron, Johnson & Johnson, and Takeda. Between earnings seasons, issues are triggered by events rather than the calendar — the January and July national formulary template drops, WAC actions, Medicare and Part D policy changes, and major launch access milestones.

The discipline is two pages. Executives forward two pages. Nobody forwards twelve.

Editorial standards

• Independence. No compensation from any issuer, payer, pharmacy benefit manager, or other entity discussed. No sponsored content, ever.
• Public sources only. Every issue is built exclusively from publicly available information — company releases, earnings call transcripts, regulatory filings, and published formulary documentation. No material non-public information appears in this publication.
• Sourcing and opinion are separated. Statements of fact are attributed. Analysis and forward-looking interpretation are clearly the author's opinion, and are labelled as such.
• Errors are corrected in public. Any material correction is noted in the following issue rather than quietly amended.

The author

Coverage Alpha is written by a practitioner rather than an observer: a decade spanning healthcare investment banking, pharmacy benefit manager formulary contracting, and pharmaceutical market access strategy — the rooms where coverage and net price are actually decided.

People holding that seat almost never publish. That is the product.